Sort
21,453 grants matching “tuberculosis”
The role of FENDRR in host defense against Mycobacterium tuberculosis infection
$1,192,312Yong Cheng · Oklahoma State University Stillwater · R01 · FY2025 · AI
Population Based Molecular Epidemiology of TB
$1,192,284University Of California San Francisco · R01 · FY2005 · AI
Production of Pedigreed SPF Rhesus Macaques
$1,190,470Rhonda S Oates · University Of California At Davis · U42 · FY2025 · OD
Production of Pedigreed SPF Rhesus Macaques
$1,190,470Jeffrey A Roberts · University Of California At Davis · U42 · FY2024 · OD
Structures of Mtb proteins conferring susceptibility to known Mtb inhibitors
$1,190,346James C Sacchettini · Texas A&M University · U01 · FY2014 · GM
THWART-TB : Testing Health Workers At Risk to advance our understanding of TB infection
$1,189,520Ruvandhi Nathavitharana · Beth Israel Deaconess Medical Center · DP2 · FY2023 · AI
ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)
$1,189,451University Of Alabama At Birmingham · U01 · FY2001 · AI
Vaccine and Treatment Evaluation Unit at Saint Louis University
$1,189,190Daniel F. Hoft · Saint Louis University · UM1 · FY2024 · AI
HARLEM AIDS TREATMENT GROUP-'CPCRA'
$1,188,323Columbia University Health Sciences · U01 · FY2005 · AI
Innate inflammatory responses during pulmonary infections
$1,188,232Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Chicago Clinical Trials Unit
$1,185,973Babafemi O Taiwo · Northwestern University At Chicago · UM1 · FY2022 · AI
A Global Research Resource for Human Tuberculosis
$1,185,782Adrie Jc Steyn · University Of Alabama At Birmingham · R24 · FY2024 · AI
Technology-Dev-Core
$1,184,948Sally M McFall · Northwestern University · U54 · FY2022 · EB
Integrating Structive Activity, Biokinetics and Response for ENP Risk Assessment
$1,184,658Joel G Pounds · Battelle Pacific Northwest Laboratories · U19 · FY2012 · ES
Collaborative African Genomics Network (CAFGEN)
$1,184,259Gabriel Anabwani · Botswana Baylor Child/Clincal Ctr/Excell · U54 · FY2015 · AI
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)
$1,181,637Charles W. Flexner · Johns Hopkins University · R24 · FY2025 · AI
Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing
$1,181,599Mark Middleton · Starks Associates, Inc. · N01 · FY2022 · AI
Core E Animal Infection Models
$1,181,034David S Perlin · Hackensack University Medical Center · U19 · FY2022 · AI
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
$1,180,713Serena Patricia Koenig · Brigham And Women'S Hospital · U01 · FY2023 · AI
Accuracy of the Xpert Ultra for Diagnosis of Pulmonary Tuberculosis
$1,180,603Susan E Dorman · Medical University Of South Carolina · R01 · FY2019 · AI
Conditionally replicating Mycobacterium tuberculosis vaccines
$1,180,499Sabine Ehrt · Weill Medical Coll Of Cornell Univ · R01 · FY2019 · AI
Project-002
$1,180,070Alessandro Sette · La Jolla Institute For Immunology · U19 · FY2020 · AI
Synthesis of Therapeutic Agents for Treatment of Infectious Diseases
$1,179,826David Starks · Starks Associates, Inc. · N01 · FY2014 · AI
Development Of New Chemotherapeutics For Tuberculosis
$1,179,135Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Experimental Animal Models of TB: Chemotherapeutics and Imaging
$1,179,135Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI